Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | PLIN5 | Q00G26 | 1/20 | 0.53 |
| ▸ | ABHD5 | Q8WTS1 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | RPS6KA2 | Q15349 | 2/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1305927 | 0.82 | DRD3 (0.44) | — | |
| SCHEMBL4124410 | 0.82 | ALDH1A1 (0.54) | ALDH1A1MAPTPLIN1HPGDALOX15 | |
| SCHEMBL2705935 | 0.82 | HPGD (0.50) | ALDH1A1MAPTPLIN1HPGDALOX15 | |
| SCHEMBL13885122 | 0.80 | ALDH1A1 (0.50) | ALDH1A1MAPTPLIN1HPGDALOX15 | |
| SCHEMBL24359432 | 0.79 | RAB9A (0.50) | ALDH1A1MAPTHPGDRAB9ACASP3 | |
| SCHEMBL17427523 | 0.75 | HPGD (0.50) | ALDH1A1MAPTPLIN1HPGDALOX15 | |
| SCHEMBL28492833 | 0.75 | ELANE (0.58) | ALDH1A1MAPTPLIN1HPGDALOX15 | |
| SCHEMBL3421267 | 0.75 | CA12 (0.52) | ALDH1A1MAPTPLIN1HPGDALOX15 | |
| SCHEMBL11949603 | 0.75 | CASP3 (0.47) | ALDH1A1CASP3CA12CA9 | |
| SCHEMBL12238555 | 0.74 | ELANE (0.43) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8987284-B2 | Phosphorus containing quinazoline compounds and methods of use | NEWGEN THERAPEUTICS, INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | NEWGEN THERAPEUTICS, INC. | 2012-08-02 | — | — | US | disclosed |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | JIANG TAO | 2009-07-30 | — | — | US | disclosed |
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| US-7514556-B2 | Inhibitors of β-lactamase | METHYLGENE INC. (CA) | 2009-04-07 | — | — | US | disclosed |
| CN-101125864-A | Heteroaromatic inhibitor for fructose-1,6-bisphosphatase | METABASIS THERAPEUTICS INC (US) | 2008-02-20 | — | — | CN | disclosed |
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2008-01-17 | — | — | US | disclosed |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | METABASIS THERAPEUTICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-7312219-B2 | Heteroaromatic inhibitors of fructose 1,6-bisphosphatase | METABASIS THERAPEUTICS, INC. (US) | 2007-12-25 | — | — | US | disclosed |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | METHYLGENE, INC. (CA) | 2007-12-20 | — | — | US | disclosed |
| WO-2000038666-A2 | A COMBINATION OF FBPase INHIBITORS AND INSULIN SENSITIZERS FOR THE TREATMENT OF DIABETES | METABASIS THERAPEUTICS, INC. (US) | 2000-07-06 | — | — | WO | disclosed |
| WO-2000014095-A1 | NOVEL HETEROAROMATIC INHIBITORS OF FRUCTOSE 1,6-BISPHOSPHATASE | METABASIS THERAPEUTICS, INC. (US) | 2000-03-16 | — | — | WO | disclosed |
| EP-0592367-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1994-04-13 | — | — | EP | disclosed |
| US-5294632-A | Diuretics and vasorelaxants | CIBA-GEIGY CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| EP-0511940-A2 | Phosphono/biaryl substituted dipeptide derivatives | CIBA-GEIGY AG (CH) | 1992-11-04 | — | — | EP | disclosed |
| US-5155100-A | Treating cardiovascular disorders in mammals | CIBA-GEIGY CORPORATION (US) | 1992-10-13 | — | — | US | disclosed |
| US-4211703-A | CHEMICAL INTERMEDIATES FOR CEPHALOSPORINS | SMITHKLINE CORPORATION (US) | 1980-07-08 | — | — | US | disclosed |
| US-4189573-A | CHEMICAL INTERMEDIATES | SMITHKLINE CORPORATION (US) | 1980-02-19 | — | — | US | disclosed |
| US-4112086-A | BACTERICIDE | SMITHKLINE CORPORATION (US) | 1978-09-05 | — | — | US | disclosed |
| US-4022761-A | HORMONES | PARKE, DAVIS & COMPANY (US) | 1977-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015195-A1 | Novel Heteroaromatic Inhibitors of Fructose-1,6-Bisphosphatase | FBP1, ALDOA, G6PC1 | ALDH1A1 640/4885MAPT 2935/4885PLIN1 861/4885 |
| US-20090192121-A1 | NOVEL BISAMIDATE PHOSPHONATE PRODRUGS | FBP1, PFKFB1, PFKFB2 | ALDH1A1 1609/4885MAPT 1651/4885PLIN1 1455/4885 |
| US-20070293675-A1 | Novel Inhibitors Of Beta-Lactamase | MGAM, LSS, CYP51A1 | ALDH1A1 1276/4885MAPT 3410/4885PLIN1 993/4885 |
| US-20120196833-A1 | PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE | PPIP5K2, PIK3CA, PHKA1 | ALDH1A1 4398/4885MAPT 4709/4885PLIN1 1061/4885 |
| US-20080004226-A1 | Combination of FBPase Inhibitors and Insulin Sensitizers for the Treatment of Diabetes | FBP1, G6PC1, IRS1 | ALDH1A1 3879/4885MAPT 2930/4885PLIN1 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.